BioNTech
BiotechMainz, Germany, Germany · Est. 2008 · 5,200 employees
BioNTech is a German biotechnology company that develops mRNA-based therapeutics and vaccines for cancer and infectious diseases.
27
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
23
Indications↗
Distinct diseases across all programs
84
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
27 drugs in development
Phase 34
Phase 29
Phase 15
Preclinical7
By Therapeutic Area
top 2
Oncology
2074%
Infectious Disease
726%
R&D Momentum
66/100
Pipeline Velocity
42/100
Trial Completion Rate
78/100
Pipeline Concentration
62/100
Pipeline Freshness
83/100
Activity
Recent Activity
Last 14 days
Jul 10, 2026
Recruiting
A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Jul 10, 2026
Recruiting
Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial
Jul 2, 2026
Active, not recruiting
A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection
Jul 2, 2026
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
Jul 2, 2026
Recruiting
A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer
Jul 2, 2026
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
Jul 1, 2026
Active, not recruiting
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Jul 1, 2026
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
3 more events
Jun 27, 2026TrialA Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Jun 26, 2026TrialA Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Jun 25, 2026TrialA Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
Details
Company Info
Company Overview
$26.0B
Mkt Cap
$18.0B
Revenue
—
Cash
CEOUgur Sahin
Founded2008
Employees5,200
HQMainz, Germany, Germany
Websitebiontech.de
LinkedInCompany Page
Therapeutic Focus
oncologyinfectious diseasesimmunotherapypersonalized medicine
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease(7 drugs)
—
3
3
1
—
Infectious Disease(7 drugs)
Oncology(20 drugs)
7
2
14
4
—
Oncology(20 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)